Market OpportunityThe company survey indicates that Babesiosis prevalence could be significantly higher than CDC estimates, suggesting a larger potential market for Tafenoquine.
Product RevenueProduct revenues showed a significant year-over-year increase, despite being supply-constrained.
Sales GrowthArakoda sales continue to grow, with net product revenues reaching $607,574 in FY24, a significant increase from $253,573 in FY23.